ATP5J Antibody

1. AKT2 and XIST expression was identified as a potential biomarker participating in the effect of ATP5J in colorectal cancer PMID: 29484395
2. CF6-induced increase in apoptotic cells was blocked by immature or mature IF1, being accompanied by protein kinase B (PKB) phosphorylation. IF1 antagonizes the pro-apoptotic action of CF6 by relief of intracellular acidification and resultant phosphorylation of PKB. PMID: 26659871
3. Over-expression of the ATP5J gene correlates with cell migration and 5-fluorouracil sensitivity in colorectal cancer. PMID: 24124598
4. CF6 plays a crucial role in the development of insulin resistance and hypertension PMID: 22038518
5. The phenotypic range of retinal, peripheral and central nervous system disease expression is characterized in a single family with NARP syndrome from the ATPase 6 m.8993T>C mtDNA point mutation. PMID: 20953793
6. coupling factor 6 induces the development of systolic dysfunction and upregulation of nicotinamide adenine dinucleotide phosphate oxidase in the heart under the high-salt diet PMID: 20811295
7. CF6 is a novel risk factor for ischemic heart disease in end-stage renal disease. Synergism of this peptide and asymmetric dimethylarginine might contribute to its occurrence presumably by inhibition of prostacyclin and nitric oxide production. PMID: 14633154
8. Mutation analysis revealed the T9176C mutation in the mtATPase 6 gene (OMIM 516060) and the mutation load was above 90% in the patients with Leigh syndrome. PMID: 15709156
9. Plasma CF6 elevated in patients with acute myocardial infarction. At 3 days, plasma CF6 correlated positively with plasma creatinine kinase peak value and correlated negatively with left ventricular ejection fraction. PMID: 15785006
10. T8993G allele causes severe extrapyramidal dysfunction and Leigh disease but there is no correlation between the degree of enzyme deficiency and the severity of the phenotype. PMID: 16532470
11. Increased CF6 may be responsible in part for decreased prostacyclin observed in coronary heart disease, in particular after PTCA and stent therapy. Potential risk factor for coronary heart disease. PMID: 17456993
12. in vascular endothelial cells both CF6 (coupling factor 6) and Angiotensin II downregulate PECAM-1 (platelet/endothelial cell adhesion molecule) expression via activation of c-Src kinase PMID: 18243211
13. Coupling factor 6 enhances Src-mediated responsiveness to angiotensin II in resistance arterioles and cells. PMID: 19106112

Show More

Hide All

HGNC: 847

OMIM: 603152

KEGG: hsa:522

STRING: 9606.ENSP00000389649

UniGene: Hs.246310